Epithelioid granulomatous lesions express abundant programmed death ligand-1 (PD-L1): a discussion of adverse events in anti-PD-1 antibody-based cancer immunotherapy
- 11 February 2021
- journal article
- research article
- Published by Taylor & Francis Ltd in Human Vaccines & Immunotherapeutics
- Vol. 17 (7), 1940-1942
- https://doi.org/10.1080/21645515.2020.1870364
Abstract
The immune system is often called a double-edged sword, due to the inextricable link between cancer immunity and allergy/autoimmunity. Intriguingly, a growing number of cases have been reported in which PD-1 blockade triggers the exacerbation of tuberculosis (TB), an organ-invasive granulomatous disease caused by bacterial infection. As a result, the exacerbation of TB is now considered a severe adverse effect of nivolumab and pembrolizumab. In this letter, we report the strong expression of PD-L1 in epithelioid granulomatous lesions in tuberculosis, sarcoidosis, Crohn’s disease, and foreign body granuloma. In addition, we discussed the exacerbation of tuberculosis after anti-PD-1 antibody-based cancer immunotherapy.Keywords
This publication has 5 references indexed in Scilit:
- Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasisEuropean Journal of Cancer, 2020
- PD-1/PD-L1 Pathway Modulates Macrophage Susceptibility to Mycobacterium tuberculosis Specific CD8+ T cell Induced DeathScientific Reports, 2019
- Tuberculosis following PD-1 blockade for cancer immunotherapyScience Translational Medicine, 2019
- Programmed death-1 (PD-1)–deficient mice are extraordinarily sensitive to tuberculosisProceedings of the National Academy of Sciences of the United States of America, 2010
- Apoptosis, but not necrosis, of infected monocytes is coupled with killing of intracellular bacillus Calmette-Guérin.The Journal of Experimental Medicine, 1994